Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionGroupama Asset Managment
Latest Disclosed Ownership165,897 shares
Latest Disclosed Value $ 74,079,646
Groupama Asset Managment reports 1.69% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 22, 2026 - Groupama Asset Managment filed a 13F-HR form disclosing ownership of 165,897 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $74,079,646 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 27, 2026 disclosing 163,144 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 1.69% during the quarter. The current value of the position is $74,127,757 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-22 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 165,897 2,753 1.69 74,080 0.16 1.0820
2026-02-27 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 163,144 119,763 276.07 73,963 335.35 1.0829
2025-12-01 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 43,381 -17,916 -29.23 16,990 -37.19 0.2490
2025-08-13 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 61,297 9,364 18.03 27,050 5.72 0.4475
2025-05-14 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 51,933 8,454 19.44 25,587 47.36 0.5112
2025-02-12 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 43,479 9,149 26.65 17,363 35.46 0.3548
2024-11-15 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 34,330 3,739 12.22 12,818 -10.60 0.3330
2024-08-14 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 30,591 20,033 189.74 14,339 17.12 0.1945
2024-05-14 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 10,558 -14,481 -57.83 12,242 20.13 0.2230
2024-02-14 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 25,039 25,039 10,191 0.2654
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.